On this page
Bietti crystalline corneoretinal dystrophy
This condition affects both eyes, typically leading to night blindness, reduced central vision, and peripheral vision loss. It is caused by genetic changes that disrupt normal fat metabolism, leading to pigment and crystal accumulation in eye tissues.
Overview
Bietti crystalline corneoretinal dystrophy (BCD) is a rare genetic eye disorder that progressively impairs vision. It typically affects both eyes, with symptoms often becoming noticeable in young adulthood. The condition is characterised by the presence of yellowish-white crystalline deposits that accumulate in the retina and sometimes the cornea. The retina is the light-sensitive tissue at the back of the eye that sends visual information to the brain, while the cornea is the clear outer layer at the front of the eye [PMID:33659223].
Over time, these crystalline deposits and associated pigment changes can lead to the degeneration of the retinal pigment epithelium and photoreceptor cells. Photoreceptor cells, specifically rods and cones, are crucial for detecting light and colour. Their deterioration results in worsening vision, which can significantly affect daily life. There is currently no cure for BCD, but management focuses on monitoring progression and supporting individuals with vision impairment.
Symptoms & clinical features
The initial symptoms of BCD often include reduced night vision, known as nyctalopia, which may appear in the late teens or early twenties. As the condition advances, individuals may experience progressive visual field loss, meaning they lose parts of their peripheral (side) vision. Central vision, essential for tasks like reading and recognising faces, can also become impaired [PMID:24076361].
Other symptoms can include photophobia (sensitivity to light) and difficulties with colour perception. The presence of crystalline deposits can sometimes be observed during a routine eye examination, particularly in the retina. In some cases, tiny crystals might also be visible in the cornea, though corneal involvement is less common than retinal involvement and usually does not cause significant vision problems on its own.
Video: Genetics 101
Affected organs
The primary organs affected in BCD are the eyes, specifically the retina and, less commonly, the cornea. The retina undergoes a process of degeneration where the light-sensing photoreceptor cells and the supporting retinal pigment epithelium gradually break down. This breakdown is accompanied by the accumulation of crystalline deposits and abnormal pigment. These changes disrupt the retina's ability to process light and send clear signals to the brain.
While the main impact is on the retina, crystalline deposits can also be found in the cornea, the clear, dome-shaped front surface of the eye. However, these corneal crystals typically do not lead to significant vision loss or discomfort compared to the retinal degeneration.
Risks & severity
BCD is a progressive condition, meaning that vision loss typically worsens over time. The age of onset usually ranges from the second to third decade of life, although some individuals may experience symptoms earlier or later. The severity of vision loss can vary between individuals, even within the same family, but it generally leads to significant visual impairment by middle age [PMID:20067645].
There are no known external risk factors that increase the likelihood of developing BCD, as it is a genetic condition. The rate of progression of vision loss also varies, and it is not currently possible to predict precisely how quickly an individual's vision will decline. Regular ophthalmic examinations are important for monitoring the disease progression.
Genetic causes
While a specific gene for Bietti crystalline corneoretinal dystrophy is not listed in our reference dataset, research has primarily linked this condition to changes in the CYP4V2 gene. This gene provides instructions for making an enzyme involved in lipid (fat) metabolism [PMID:20067645].
Pathogenic variants in CYP4V2 are thought to disrupt the normal processing of certain fats, leading to their abnormal accumulation. This accumulation manifests as the characteristic crystalline and pigment deposits observed in the retina and cornea, ultimately contributing to the degeneration of these eye tissues. Understanding the genetic cause helps explain the underlying biological mechanisms of the disease.
Inheritance pattern
Bietti crystalline corneoretinal dystrophy has an autosomal recessive inheritance pattern. This means that an individual must inherit two altered copies of the causative gene - one from each parent - to develop the condition. People who inherit only one altered copy are called carriers; they typically do not show symptoms of the condition themselves but can pass the altered gene copy on to their children.
If both parents are carriers of a pathogenic variant, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies and develop BCD. There is a 50% (1 in 2) chance that their child will be a carrier like them, and a 25% chance that their child will inherit two unaffected copies and not be a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of Bietti crystalline corneoretinal dystrophy typically begins with a comprehensive eye examination by an ophthalmologist. The presence of characteristic crystalline deposits in the retina, along with progressive retinal atrophy and pigmentary changes, often provides strong indicators. Imaging techniques such as fundus autofluorescence and optical coherence tomography (OCT) are widely used to assess the extent of retinal damage and confirm the presence of crystals [PMID:33659223].
Genetic testing is crucial to confirm the diagnosis, especially given the genetic basis of BCD. Such testing, typically through a blood or saliva sample, involves analysing specific genes, such as CYP4V2, for pathogenic variants. Referral for genetic testing, which aligns with NHS Genomic Medicine Service pathways, would generally be made by an ophthalmologist or a clinical geneticist. In the UK, genetic testing for inherited eye conditions can be requested through relevant R-codes, such as those covered by the Genomic Medicine Service for inherited retinal disorders.
Management & lifestyle
Currently, there is no specific treatment to reverse or stop the progression of Bietti crystalline corneoretinal dystrophy. Management therefore focuses on monitoring the condition and supporting individuals with vision impairment. Regular eye examinations are important to track disease progression and address any secondary complications.
Patients are typically supported by low vision services, which can provide magnifiers, specialised lighting, and other adaptive aids to help manage daily activities. Genetic counselling is also recommended for affected individuals and their families to understand the inheritance pattern, discuss reproductive options, and provide emotional support. While ongoing research explores potential therapies, current care in the NHS focuses on symptomatic support and regular monitoring.
UK care pathway
For individuals in the UK suspected of having Bietti crystalline corneoretinal dystrophy, the care pathway typically involves referral to specialist ophthalmology services. If an inherited eye condition is suspected, they may then be referred to a clinical genetics service. These services work within the NHS Genomic Medicine Service framework, which can facilitate genetic testing using specific R-codes for inherited retinal dystrophies. Genetic counsellors play a vital role, offering information, support, and guidance on the implications of a genetic diagnosis for the individual and their family.
Frequently asked questions
What is life like for someone with Bietti crystalline corneoretinal dystrophy?
Life with BCD involves adapting to progressive vision loss, starting with difficulties in low light and gradually affecting central and peripheral vision. Individuals often utilise low vision aids and support services to maintain independence and quality of life. Regular check-ups with an ophthalmologist are important for managing the condition.
Are there any treatments for Bietti crystalline corneoretinal dystrophy?
Currently, there isn't a cure or specific treatment to halt the progression of BCD. Management focuses on supporting individuals with their vision using low vision aids and regular monitoring of the condition. Research is ongoing to explore potential future therapies.
How is Bietti crystalline corneoretinal dystrophy diagnosed?
Diagnosis typically involves a comprehensive eye examination by an ophthalmologist, including special scans of the retina. This often reveals characteristic crystalline deposits and retinal changes. Genetic testing, usually performed on a blood sample, can confirm the diagnosis by identifying specific genetic changes.
If I have Bietti crystalline corneoretinal dystrophy, what does this mean for my children?
BCD is inherited in an autosomal recessive manner. If you have the condition, it means you have two altered gene copies. Your children would inherit one altered copy from you. If your partner also carries an altered copy of the same gene, there would be a risk for your children to also have BCD. Genetic counselling can provide personalised risk assessments and discuss family planning options.
Can Bietti crystalline corneoretinal dystrophy affect other parts of my body?
While the primary impact of BCD is on the eyes, particularly the retina and occasionally the cornea, it is not typically known to cause symptoms or issues in other parts of the body. The genetic changes associated with BCD primarily affect fat metabolism within the eye tissues.
References
- Adam MP, Bick S, Mirzaa GM. Bietti Crystalline Dystrophy. 1993. PMID: 22497028
- Georgiou M, Robson AG, Fujinami K. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Progress in retinal and eye research. 2024. PMID: 38278208
- Wang J, Zhang J, Yu S. Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial. Signal transduction and targeted therapy. 2024. PMID: 38653979
- Zhao G, Ding D. Bietti crystalline corneoretinal dystrophy: Advances in understanding and gene therapeutic approaches. Molecular vision. 2025. PMID: 41306488
- Jia R, Chen S, Li W. Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy. Progress in retinal and eye research. 2025. PMID: 40482806
- Meng X, Jia R, Zhao X. In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment. Nature communications. 2024. PMID: 38710738
- Yang L, Xing D, Zhang J. Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial. Molecular therapy : the journal of the American Society of Gene Therapy. 2026. PMID: 41520174
- Jiao X, Li A, Jin ZB. Identification and population history of CYP4V2 mutations in patients with Bietti crystalline corneoretinal dystrophy. European journal of human genetics : EJHG. 2017. PMID: 28051075